SARC Biannual Meeting Agenda

8:00 am - 12:00 pm

8:00 – 8:15 Welcome/SARC Update Laurence Baker, Chair, SARC Board of Directors

• PET Evaluation of Sarcoma Treatment Response: “PERCIST” Criteria Richard Wahl
• Assessing Response in Sarcomas: Methods Are Clear; Results Are Murky Scott Schuetze

9:20-9:35 Brief Update: Selected Ongoing and Recently Completed SARC Trials Laurence Baker

• SARC 003 Phase 2 Gemcitabine/Docetaxel in Bone Sarcoma
• SARC 004 Phase 2 Neoadjuvant Imatinib in DFSP
• SARC 005 Phase 2 Adjuvant Therapy High Risk Uterine Leiomyosarcoma
• SARC 007 Phase 2 Perifosine in chemoinsensitive sarcoma
• SARC 009 Phase 2 Dasatinib in metastatic sarcoma

9:50-10:10 New directions in therapy for MPNST Brigitte Widemann

• SARC 006 Phase 2 Sporadic vs. NF-associated MPNST
• SARC 016 Phase 2 RAD001 with and without bevacizumab in metastatic MPNST

10:10-10:30 Rationale and study of IGF-1R in Ewing sarcoma Lee Helman

• SARC011 Phase 2 IGF-1R in Ewing’s in selected sarcoma subtypes Alberto Pappo
• SARC013 Phase 3 Chemotherapy and R1507 or placebo in metastatic Ewing’s Paul Meyers

10:30-10:50 Advancing care of GIST patients George Demetri

• SARC 015 Phase 2 R1507 in wild-type GIST Katie Janeway
• SARC 009 Phase 2 Dasatinib in metastatic GIST Jonathan Trent
• SARC 019 Phase 3 Imatinib PK testing in metastatic GIST Suzanne George

10:50-11:10 Src Kinase Inhibition of Osteosarcoma Su Young Kim

• SARC 012 Phase 2 Sarcatinib in recurrent osteosarcoma/SARC009 Dasatinib in the osteosarcoma cohort

11:10-11:30 Collaboration with EORTC Bihn Bui

• EORTC 62091/SARC020 Phase 2b EORTC study of ET743 in metastatic STS

(SARC Participants Only)